会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 22. 发明申请
    • SMALL MOLECULE BCL-X1/BCL-2 BINDING INHIBITORS
    • 小分子BCL-X1 / BCL-2结合抑制剂
    • US20100168184A1
    • 2010-07-01
    • US12652456
    • 2010-01-05
    • Ching-Shih ChenChung-Wai Shiau
    • Ching-Shih ChenChung-Wai Shiau
    • A61K31/352A61K31/427A61K31/4439A61K31/426A61P35/00
    • C07D417/12C07D277/34C07D311/58C07D417/14
    • Bcl-xL/Bcl-2 binding inhibitors useful in the treatment of unwanted proliferating cells, including cancers and precancers, in subjects in need of such treatment. Also provided are methods of treating a subject having unwanted proliferating cells comprising administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject in need of such treatment. Also provided are methods of preventing the proliferation of unwanted proliferating cells, such as cancers and precancers, in a subject comprising the step of administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject at risk of developing a condition characterized by unwanted proliferating cells.
    • Bcl-xL / Bcl-2结合抑制剂可用于治疗需要这种治疗的受试者中不需要的增殖细胞,包括癌症和预处理剂。 还提供了治疗具有不想要的增殖细胞的受试者的方法,包括向需要这种治疗的受试者施用治疗有效量的本文所述的Bcl-xL / Bcl-2结合抑制剂。 还提供了防止不想要的增殖细胞如癌症和预处理剂在受试者中增殖的方法,包括将治疗有效量的本文所述的Bcl-xL / Bcl-2结合抑制剂施用于患有风险的受试者的步骤 发展以不想要的增殖细胞为特征的病症。
    • 23. 发明申请
    • Treatment of Prostate Cancer with Angiogenesis-Targeting Quinazoline-Based Anti-Cancer Compounds
    • 用血管发生靶向喹唑啉类抗癌化合物治疗前列腺癌
    • US20090170865A1
    • 2009-07-02
    • US12323073
    • 2008-11-25
    • Natasha KyprianouJason B. GarrisonChing-Shih Chen
    • Natasha KyprianouJason B. GarrisonChing-Shih Chen
    • A61K31/517C12N5/06
    • A61K31/517
    • Provided is a method of inhibiting the growth of prostate cancer cells comprising administering an effective amount of DZ-50 (2-[4-biphenyl-4-sulfonyl)-piperazin-1-yl]-6,7-diisopropoxyquinazolin-4-yl-amine) to a patient in need thereof. In another aspect, a method is provided for inhibiting the initiation of prostate cancer comprising administering an effective amount of DZ-50 to a patient in need thereof. In yet another aspect, a method is provided for inhibiting the formation of a prostate tumor-derived metastatic lesion comprising administering an effective amount of DZ-50 to a patient in need thereof. In any of the aforementioned methods, a quinazoline-based drug which induces apoptosis of a prostate cancer cell may be coadministered with DZ-50. Also provided is a composition comprising DZ-50, a quinazoline-based drug which induces apoptosis of a prostate cancer cell, and a pharmaceutically acceptable carrier.
    • 提供了抑制前列腺癌细胞生长的方法,其包括给予有效量的DZ-50(2- [4-联苯-4-磺酰基] - 哌嗪-1-基] -6,7-二异丙氧基喹唑啉-4-基 - 胺)给有需要的患者。 另一方面,提供了一种抑制前列腺癌起始的方法,包括向有需要的患者施用有效量的DZ-50。 在另一方面,提供了一种用于抑制前列腺肿瘤衍生的转移性病变的形成的方法,包括向有需要的患者施用有效量的DZ-50。 在任何上述方法中,诱导前列腺癌细胞凋亡的基于喹唑啉的药物可以与DZ-50共同施用。 还提供了包含诱导前列腺癌细胞凋亡的基于喹唑啉的药物DZ-50和药学上可接受的载体的组合物。
    • 25. 发明申请
    • PDK-1/AKT SIGNALING INHIBITORS
    • PDK-1 / AKT信号抑制剂
    • US20080146815A1
    • 2008-06-19
    • US11864612
    • 2007-09-28
    • Ching-Shih Chen
    • Ching-Shih Chen
    • C07D257/04C07D231/10
    • C07D231/12
    • A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I: wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthryl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, C1-C4 alkyl, C1-C4 haloalkyl, azido, C1-C4 azidoalkyl, aryl, alkylaryl, haloaryl, haloalkylaryl, and combinations thereof, and R is selected from the group consisting of nitrile, acetonitrile, ethylnitrile, propylnitrile, carboxamide, amidine, tetrazole, oxime, hydrazone, acetamidine, aminoacetamide, guanidine, and urea. Also provided are methods of using the compounds for the treatment and prevention of cancer in humans.
    • 新型的式I的磷酸肌醇依赖性激酶-1(PDK-1)抑制剂:其中X选自烷基和卤代烷基; Ar是选自苯基,联苯基,萘基,蒽基,菲基和芴基的芳基; 并且其中Ar任选被一个或多个选自以下的基团取代:卤素,C 1 -C 4烷基,C 1〜 C 4卤代烷基,叠氮基,C 1 -C 4 - 叠氮基烷基,芳基,烷基芳基,卤代芳基,卤代烷基芳基及其组合,并且选择R 腈,乙腈,丙腈,甲酰胺,脒,四唑,肟,腙,乙脒,氨基乙酰胺,胍和尿素组成的组。 还提供了使用该化合物治疗和预防人类癌症的方法。
    • 26. 发明申请
    • Compounds and methods for inducing apoptosis in proliferating cells
    • 用于诱导增殖细胞凋亡的化合物和方法
    • US20060142368A1
    • 2006-06-29
    • US11354528
    • 2006-02-15
    • Ching-Shih ChenXueqin SongHo-Pi Lin
    • Ching-Shih ChenXueqin SongHo-Pi Lin
    • A61K31/415
    • A61K31/415
    • Compounds useful for inducing apoptosis in proliferative cells, particularly cancer cells, including but not limited to prostate cancer, leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, bladder cancer, lymphoma, and breast cancer. These compounds are particularly useful in the treatment of androgen-independent cancers, including hormone-refractory prostate cancer. Further provided are methods of treating cancer in a subject in need of such treatment using the compounds of the present invention. Further provided are methods for using the compounds of the present invention to treat, inhibit, or delay the onset of cancer in a subject. Further provided are methods of inducing apoptosis in rapidly proliferating cells, particularly, though not necessarily cancer cells, using the compounds of the present invention.
    • 包括但不限于前列腺癌,白血病,非小细胞肺癌,结肠癌,CNS癌,黑素瘤,卵巢癌,肾癌,膀胱癌,淋巴瘤和增殖细胞中的诱导细胞凋亡的化合物, 乳腺癌。 这些化合物特别可用于治疗与雄激素无关的癌症,包括激素难治性前列腺癌。 还提供了使用本发明的化合物治疗需要这种治疗的受试者的癌症的方法。 还提供了使用本发明化合物治疗,抑制或延迟受试者的癌症发作的方法。 还提供了使用本发明的化合物诱导快速增殖的细胞,特别是尽管不一定是癌细胞的细胞凋亡的方法。
    • 28. 发明授权
    • Automatic liquid soap dispenser
    • 液体皂液自动分配器
    • US5507413A
    • 1996-04-16
    • US297284
    • 1994-08-29
    • Ching-Shih Chen
    • Ching-Shih Chen
    • A47K5/12G01F11/02B67D5/08
    • A47K5/1217G01F11/021G01F11/029Y10S4/903
    • An automatic liquid soap dispenser includes a liquid soap container which receives liquid soap therein and which has a bottom wall that is formed with an outlet port. A tubular body is secured to a bottom surface of the bottom wall such that a through-hole at a closed rear portion of the tubular body is aligned with the outlet port. The closed rear portion of the tubular body is further formed with an upright soap outlet adjacent to the through-hole. A movable blocking member is provided adjacent to said closed rear portion and is movable to block and unblock the through-hole so as to control the flow of the liquid soap through the soap outlet. The plunger has a piston which extends fittingly and movably into the tubular body via an open front portion of the latter, and a flexible shaft portion connected to the piston. A driving unit is activated by a detecting unit upon detection of a target. The shaft portion of the plunger is coupled eccentrically to the driving unit so that activation of the driving unit results in reciprocal linear movement of the piston within the tubular body to dispense a predetermined amount of the liquid soap through the soap outlet. A switch unit is activated when the piston of the plunger completes one cycle of the reciprocal linear movement and deactivates the driving unit when activated.
    • 自动液体皂分配器包括在其中容纳液体皂的液体肥皂容器,并且具有形成有出口的底壁。 管状体固定到底壁的底表面,使得管状体的封闭后部的通孔与出口对准。 管状体的封闭后部还形成有与通孔相邻的直立肥皂出口。 一个可移动的阻挡件邻近所述封闭的后部设置并且可移动以阻挡和解除通孔,从而控制液体肥皂通过肥皂出口的流动。 柱塞具有活塞,该活塞经由其后部的敞开的前部而适配地且可移动地延伸到管状体中,以及连接到活塞的柔性轴部。 在检测到目标时,由检测单元激活驱动单元。 柱塞的轴部分偏心地联接到驱动单元,使得驱动单元的启动导致活塞在管状体内的往复线性运动,以通过肥皂出口分配预定量的液体肥皂。 当活塞的活塞完成往复线性运动的一个循环并且当激活时停用驱动单元时,开关单元被激活。